American Society of Hirudotherapy

Hman1 (Hirudinaria manillensis Macin)

Conserved cysteine-stabilized αβ macin from the Asian buffalo leech — Yu 2025 demonstrates retained antimicrobial function while Hman2/Hman3 paralogs degenerate.

Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Conserved cysteine-stabilized αβ macin from the Asian buffalo leech — Yu 2025 demonstrates retained antimicrobial function while Hman2/Hman3 paralogs degenerate.
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Antibiotic stewardship

Clinical translation limit

Hman1's predicted antimicrobial activity is inferred from sequence conservation and expression patterns. No FDA-approved derivative; H. manillensis is not on the FDA K040187 cleared device species list.

Molecular Profile

Category
Antimicrobial
Evidence tier
Preclinical
Source species
Hirudinaria manillensis
Discovered
2025 · Yu Y et al.
Hman1 (Hirudinaria manillensis Macin) molecular structure

Biological Targets

  • bacterial membrane (broad-spectrum, gram-positive / gram-negative)

Key Citations

  1. Yu Y et al. (2025), Biology (Basel) · PMID 40427706

External Resources

    Related Antimicrobial Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.